Peptide record

TPDB08716

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB08716
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 18-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KIGAKIKIGAKIKIGAKI
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C87H164N24O19
RNDCEQHLMFPSTWYV
IK
1850.41
11.21
6
0
9
+6
-0.25
0.433
146.67
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
3
A
0
R
0
N
0
D
0
C
0
E
0
Q
3
G
0
H
6
I
0
L
6
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 0 I: 6 L: 0 K: 6 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
18 reviewed residue count
C87H164N24O19 sequence-only estimate (linear, free termini)
1850.41 sequence-only estimate (linear, free termini)
11.21 sequence-only estimate (linear, free termini)
+6 sequence-only estimate (linear, free termini)
-0.25 sequence-only estimate (linear, free termini)
0.433 sequence-only estimate (linear, free termini)
Evidence Records 5 records
Evidence 1 Activity

Activity

3% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
3% Hemolysis | 500 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A novel linear amphipathic beta-sheet cationic antimicrobial peptide with enhanced selectivity for bacterial lipids | J Biol Chem | 2001
Evidence 2 Activity

Activity

14% Hemolysis
Toxicity
7.5 µM
Hemolytic Cytotoxic
14% Hemolysis | 7.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Stereochemical effects on the aggregation and biological properties of the fibril-forming peptide [KIGAKI]3 in membranes. | Phys Chem Chem Phys | 2013
Evidence 3 Activity

Activity

54% Hemolysis
Toxicity
60 µM
Hemolytic Cytotoxic
54% Hemolysis | 60 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Stereochemical effects on the aggregation and biological properties of the fibril-forming peptide [KIGAKI]3 in membranes. | Phys Chem Chem Phys | 2013
Evidence 4 Activity

Activity

1% Hemolysis
Toxicity
>100 µM
Hemolytic Cytotoxic
1% Hemolysis | >100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Characterisation and evaluation of synthetic antimicrobial peptides against Bacillus globigii, Bacillus anthracis and Burkholderia thailandensis. | Int J Antimicrob Agents | 2010
Evidence 5 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis